Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Journal of Labelled Compounds and Radiopharmaceuticals is Scopus-indexed (Q3, CiteScore 1.9), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by John Wiley and Sons Ltd.
Checked against the index lists dated .
ISSN 0362-4803Verify ISSN ↗1099-1344Verify ISSN ↗
Publisher: John Wiley and Sons Ltd
Cost to publish: About US$3,800 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 236 / 361 | 34th | Q3 |
| Spectroscopy | 65 / 81 | 20th | Q4 |
| Drug Discovery | 131 / 161 | 18th | Q4 |
| Organic Chemistry | 175 / 215 | 18th | Q4 |
| Biochemistry | 365 / 448 | 18th | Q4 |
| Analytical Chemistry | 132 / 160 | 17th | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1976–present, best quartile Q3, CiteScore 1.9.
Journal of Labelled Compounds and Radiopharmaceuticals is Q3 in Radiology, Nuclear Medicine and Imaging (rank 236 of 361), Q4 in Spectroscopy (rank 65 of 81) and Q4 in Drug Discovery (rank 131 of 161), by CiteScore 2025. It is ranked in 6 subject areas in all.
Journal of Labelled Compounds and Radiopharmaceuticals is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 1.9, which places it in quartile Q3 at the 34th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.293, quartile Q3, with an H-index of 58.
The publisher lists an article processing charge of about US$3,800 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Journal of Labelled Compounds and Radiopharmaceuticals is published by John Wiley and Sons Ltd. Its print ISSN is 0362-4803 and its online ISSN is 1099-1344.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Journal of Labelled Compounds and Radiopharmaceuticals has an h-index of 67 and a 2-year mean of 0.58 citations per paper (OpenAlex). Its Scopus CiteScore is 1.9, quartile Q3. On 2-year citations it ranks #262 of 346 Scopus journals in Radiology, Nuclear Medicine and Imaging.
Journal of Labelled Compounds and Radiopharmaceuticals published 62 papers in 2025; its busiest recent year was 2017 with 156. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2023–2026), authors are most often from United States (28.2%), China (18.6%) and Japan (10.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (0.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.